Appendix 9 (as supplied by the authors): Proportion of sitagliptin and alternative hypoglycemic agent monotherapy and combination therapy users with acute pancreatitis at 90 days

| Outcome                                    | Weighted % of<br>sitagliptin<br>monotherapy<br>users<br>(unweighted %) | Weighted % of alternative hypoglycemic agent monotherapy users (unweighted %) | Weighted % of sitagliptin combination therapy users* (unweighted %) | Weighted % of<br>alternative<br>hypoglycemic<br>agent<br>combination<br>therapy users*<br>(unweighted %) |
|--|--|---|---|--|
| Hospital encounter with acute pancreatitis | 0.06% (0.06%)  | 0.09% (0.10%)   | 0.09% (0.09%)   | 0.09% (0.10%)  |

<sup>\*</sup>Combination therapy users were those who had at least one additional prescription for a hypoglycemic agent (ie a prescription apart from the study drug) which overlapped with the index date.